170 related articles for article (PubMed ID: 11193926)
1. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae.
Fiorani P; Bjornsti MA
Ann N Y Acad Sci; 2000; 922():65-75. PubMed ID: 11193926
[TBL] [Abstract][Full Text] [Related]
2. Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.
Colley WC; van der Merwe M; Vance JR; Burgin AB; Bjornsti MA
J Biol Chem; 2004 Dec; 279(52):54069-78. PubMed ID: 15489506
[TBL] [Abstract][Full Text] [Related]
3. Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.
Bjornsti MA; Knab AM; Benedetti P
Cancer Chemother Pharmacol; 1994; 34 Suppl():S1-5. PubMed ID: 8070016
[TBL] [Abstract][Full Text] [Related]
4. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
5. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.
Losasso C; Cretaio E; Palle K; Pattarello L; Bjornsti MA; Benedetti P
J Biol Chem; 2007 Mar; 282(13):9855-9864. PubMed ID: 17276985
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death.
Megonigal MD; Fertala J; Bjornsti MA
J Biol Chem; 1997 May; 272(19):12801-8. PubMed ID: 9139740
[TBL] [Abstract][Full Text] [Related]
7. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.
Jacquiau HR; van Waardenburg RC; Reid RJ; Woo MH; Guo H; Johnson ES; Bjornsti MA
J Biol Chem; 2005 Jun; 280(25):23566-75. PubMed ID: 15817450
[TBL] [Abstract][Full Text] [Related]
8. The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons.
Fiorani P; Reid RJ; Schepis A; Jacquiau HR; Guo H; Thimmaiah P; Benedetti P; Bjornsti MA
J Biol Chem; 2004 May; 279(20):21271-81. PubMed ID: 14990574
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants.
Knab AM; Fertala J; Bjornsti MA
J Biol Chem; 1993 Oct; 268(30):22322-30. PubMed ID: 8226741
[TBL] [Abstract][Full Text] [Related]
10. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
van der Merwe M; Bjornsti MA
J Biol Chem; 2008 Feb; 283(6):3305-3315. PubMed ID: 18056711
[TBL] [Abstract][Full Text] [Related]
11. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
Fertala J; Vance JR; Pourquier P; Pommier Y; Bjornsti MA
J Biol Chem; 2000 May; 275(20):15246-53. PubMed ID: 10809761
[TBL] [Abstract][Full Text] [Related]
12. Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I.
Hann C; Evans DL; Fertala J; Benedetti P; Bjornsti MA; Hall DJ
J Biol Chem; 1998 Apr; 273(14):8425-33. PubMed ID: 9525954
[TBL] [Abstract][Full Text] [Related]
13. CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage.
Reid RJ; Fiorani P; Sugawara M; Bjornsti MA
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11440-5. PubMed ID: 10500195
[TBL] [Abstract][Full Text] [Related]
14. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae.
Pouliot JJ; Robertson CA; Nash HA
Genes Cells; 2001 Aug; 6(8):677-87. PubMed ID: 11532027
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Nitiss JL; Wang JC
Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
[TBL] [Abstract][Full Text] [Related]
16. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.
Woo MH; Losasso C; Guo H; Pattarello L; Benedetti P; Bjornsti MA
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13767-72. PubMed ID: 14585933
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast.
Reid RJ; Kauh EA; Bjornsti MA
J Biol Chem; 1997 May; 272(18):12091-9. PubMed ID: 9115278
[TBL] [Abstract][Full Text] [Related]
18. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA
J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
20. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons.
Knab AM; Fertala J; Bjornsti MA
J Biol Chem; 1995 Mar; 270(11):6141-8. PubMed ID: 7890748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
